이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행성 고형 종양이 있는 참가자에서 PF-07220060의 안전성 및 내약성을 테스트하기 위한 연구 (CDK4i)

2026년 11월 5일 업데이트: Pfizer

PF-07220060의 안전성, 내약성, 약동학, 약력학 및 항종양 활성을 단일 제제로 그리고 진행성 고형 종양이 있는 참가자의 병용 요법의 일부로 평가하는 1/1B상 연구

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.

Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort.

Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide.

The Giredestrant Combination Cohort will evaluate PF-07220060 in combination with giredestrant.

In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine the maximum tolerated dose (MTD) and select the recommended dose for expansion.

In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine therapies (letrozole and fulvestrant, respectively).

In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from Part 1A will be conducted.

In Part 1E, the effect of PF-07220060 on the PK of midazolam will be evaluated (DDI).

In Part 1F, escalating doses of PF-07220060 will be administered in combination with enzalutamide.

In Part 1G, PF-07220060 will be administered in combination with tamoxifen to determine the RDE.

Part 2A is an expansion cohort for PF-07220060 in combination with fulvestrant and will explore more than one dose of PF-07220060.

Part 2B and Part 2C are expansion cohorts for PF-07220060 in combination with letrozole and fulvestrant, respectively.

Part 2E is an expansion cohort to evaluate PF-07220060 Monotherapy versus PF-07220060 plus fulvestrant combination therapy.

Part 2F is an expansion cohort for PF-07220060 in combination with tamoxifen. The Giredestrant Combination Cohort Group A will determine the tolerable dose of PF-07220060 in combination with giredestrant. In Group B, additional participants will be enrolled at the tolerable dose to further assess safety and PK.

The China and Japan monotherapy cohorts will evaluate safety, tolerability, and PK of PF-07220060 as single agent in Chinese and Japanese participants, respectively.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

430

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Oaxaca City, 멕시코, 68000
        • 모집하지 않고 적극적으로
        • Oaxaca Site Management Organization
    • Mexico City
      • Mexico City, Mexico City, 멕시코, 04700
        • 모집하지 않고 적극적으로
        • COI Centro Oncologico Internacional S.A.P.I. de C.V.
      • Mexico City, Mexico City, 멕시코, 04700
        • 모집하지 않고 적극적으로
        • Hospital MAC Periferico Sur
      • Mexico City, Mexico City, 멕시코, 14080
        • 모집하지 않고 적극적으로
        • INCAN
    • Nuevo León
      • Monterrey, Nuevo León, 멕시코, 64460
        • 모집하지 않고 적극적으로
        • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    • Oaxaca
      • Oaxaca City, Oaxaca, 멕시코, 68000
        • 모집하지 않고 적극적으로
        • Hospital Reforma
    • California
      • Los Angeles, California, 미국, 90064
        • 모병
        • Ellison Institute
    • Connecticut
      • New Haven, Connecticut, 미국, 06511
        • 모병
        • Smilow Cancer Hospital Phase 1 Unit
      • New Haven, Connecticut, 미국, 06510
        • 모병
        • Yale-New Haven Hospital-Yale Cancer Center
      • New Haven, Connecticut, 미국, 06510
        • 모병
        • Smilow Cancer Hospital - Yale New Haven Health
      • New Haven, Connecticut, 미국, 06511
        • 모병
        • Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
      • Trumbull, Connecticut, 미국, 06611
        • 모병
        • Smilow Cancer Hospital - Trumbull
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • 모집하지 않고 적극적으로
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, 미국, 02115
        • 모집하지 않고 적극적으로
        • Brigham & Women's Hospital
      • Newton, Massachusetts, 미국, 02467
        • 모집하지 않고 적극적으로
        • Dana Farber Cancer Institute- Chestnut Hill
    • Michigan
      • Grand Rapids, Michigan, 미국, 49546
        • 모병
        • START Midwest
    • Tennessee
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • Sarah Cannon Research Institute - Pharmacy
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • SCRI Oncology Partners
    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • The University of Texas MD Anderson Cancer Center
      • Houston, Texas, 미국, 77079
        • 모병
        • The University of Texas, MD Anderson Cancer Center - West Houston
      • Bratislava, 슬로바키아, 833 10
        • 모집하지 않고 적극적으로
        • Narodny onkologicky ustav
      • Bratislava, 슬로바키아, 812 50
        • 모집하지 않고 적극적으로
        • Onkologicky ustav sv. Alzbety, s.r.o., Interna klinika VSZaSP a OUSA
      • Nové Zámky, 슬로바키아, 940 34
        • 모집하지 않고 적극적으로
        • Fakultna nemocnica s poliklinikou Nove Zamky
      • Buenos Aires, 아르헨티나, C1426ABP
        • 모집하지 않고 적극적으로
        • Fundación Respirar
      • Córdoba, 아르헨티나, X50004FHP
        • 모집하지 않고 적극적으로
        • Clínica Universitaria Reina Fabiola
      • La Rioja, 아르헨티나, F5300COE
        • 모집하지 않고 적극적으로
        • Fundación CORI para la Investigación y Prevención del Cáncer
    • Buenos Aires
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, 아르헨티나, 1280
        • 모집하지 않고 적극적으로
        • Hospital Británico de Buenos Aires
    • Ciudad Autã³noma de Buenos Aires
      • CABA, Ciudad Autã³noma de Buenos Aires, 아르헨티나, 1125
        • 모집하지 않고 적극적으로
        • Fundación Cenit Para La Investigación En Neurociencias
      • London, 영국, W1G 6AD
        • 모집하지 않고 적극적으로
        • Sarah Cannon Research Institute UK
      • Manchester, 영국, M20 4BX
        • 모집하지 않고 적극적으로
        • The Christie Hospital NHS Foundation Trust
    • Edinburgh, CITY of
      • Edinburgh, Edinburgh, CITY of, 영국, EH4 2XR
        • 모집하지 않고 적극적으로
        • Cancer Research UK Edinburgh Centre
    • London, CITY of
      • London, London, CITY of, 영국, EC1A 7BE
        • 모집하지 않고 적극적으로
        • St Bartholomew's Hospital
    • Chiba
      • Kashiwa, Chiba, 일본, 277-8577
        • 모집하지 않고 적극적으로
        • National Cancer Center Hospital East
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100021
        • 모집하지 않고 적극적으로
        • Cancer Hospital Chinese Academy of Medical Science
    • Henan
      • Zhengzhou, Henan, 중국, 450008
        • 모집하지 않고 적극적으로
        • Henan Cancer Hospital
    • Hubei
      • Wuhan, Hubei, 중국, 430079
        • 모집하지 않고 적극적으로
        • Hubei Cancer Hospital
    • Shanxi
      • Xi’an, Shanxi, 중국, 710061
        • 모집하지 않고 적극적으로
        • The First Affiliated Hospital of Xi'an Jiaotong University
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310016
        • 모집하지 않고 적극적으로
        • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
      • Prague, 체코, 12808
        • 모집하지 않고 적극적으로
        • Vseobecna fakultni nemocnice v Praze

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

  • Part 1: Breast Cancer (BC)

    • Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) BC
    • Part 1A/Part 1D/Part 1E also include: Refractory HR-positive/HER2-positive BC
  • Part 1: Tumors other than BC (Part 1A/Part 1D/Part 1E): NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests

  • Part 1F: prostate cancer

  • Part 1G: HR-positive/HER2-negative BC

  • Part 2A, 2B, 2C, 2E, and 2F: HR-positive/HER2-negative BC

  • Part 1D: metastatic castration resistant prostate cancer

  • Giredestrant Combination Cohort: ER-positive/HER2-negative BC

  • Prior systemic Treatment

    • Part 1: HR-positive/HER2-negative BC

      • At least 1 line of SOC, including CD4/6 inhibitor therapy for advanced or metastatic disease, or if CDK4/6 inhibitors are not considered appropriate in the opinion of the investigator
      • HR-positive/HER2-positive BC (Parts 1A/1D/1E): at least 1 prior treatment of approved HER2 targeting therapy
      • Tumors other than BC (Parts 1A/1D/1E/1F): tumor that is resistant to at least 2 lines of SOC for advanced or recurrent disease or for which no standard therapy is available
    • Part 2A and 2E: at least 1 line of standard of care (including prior CDK4/6i) for advanced/metastatic disease; Prior chemo is allowed; Prior fulvestrant, mTOR and/or PI3K inhibitors are allowed

    • Part 2B: no prior systemic anti-cancer therapies for advanced/metastatic BC

    • Part 2C:

      • Progressed during treatment or within 12 months of completion of adjuvant therapy with an aromatase inhibitor if postmenopausal, or tamoxifen if pre or perimenopausal, or
      • Progressed while on or within 1 month after the endo the prior aromatase inhibitor therapy for advanced/metastatic BC if postmenopausal or prior endocrine treatment for advanced/metastatic BC if pre or perimenopausal
      • One previous line of chemotherapy for advanced/metastatic disease is allowed in addition to endocrine therapy
    • Part 1G and 2F: at least 2 lines of SOC for advanced or metastatic disease, including CDK4/6 inhibitor and endocrine therapy

    • Giredestrant Combination Cohort: at least 1 (no more than 3) prior line(s) of SOC for advanced or metastatic disease, including CDK4/6 inhibitor and endocrine therapy

General Inclusion Criteria

  • All participants must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
  • Adequate renal, liver, and bone marrow function

Exclusion Criteria:

  • Part 2B: prior neoadjuvant or adjuvant treatment with a non-steroidal aromatase inhibitor with disease recurrence while on or within 12 months of completing treatment. Prior treatment with any CDK4/6 inhibitor
  • Part 2C: prior treatment with any CDK inhibitor, fulvestrant, everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway
  • Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease
  • Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
  • Major surgery or radiation within 4 weeks prior to study intervention
  • Last anti-cancer treatment within 2 weeks prior to study intervention; Part 1G and 2F: tamoxifen treatment within 35 days of Day -4
  • Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry
  • Part 1G and 2F: history of or current pulmonary embolism or deep vein thrombosis
  • Giredestrant Combination Cohort: history (within 6 months of screening) of or presence of idiopathic symptomatic bradycardia or resting heart rate <50 bpm at screening
  • Pregnant or breastfeeding female participant
  • Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 1A Monotherapy Escalation Arm 1

PF-07220060 Monotherapy Escalation

CDK4 inhibitor

실험적: 1A Monotherapy Escalation Arm 2

PF-07220060 Monotherapy Escalation

CDK4 inhibitor

실험적: 1A Monotherapy Escalation Arm 3

PF-07220060 Monotherapy Escalation

CDK4 inhibitor

실험적: 1A Monotherapy Escalation Arm 4

PF-07220060 Monotherapy Escalation

CDK4 inhibitor

실험적: 1A Monotherapy Escalation Arm 5

PF-07220060 Monotherapy Escalation

CDK4 inhibitor

실험적: 1B Combination Dose Finding Arm 1

PF-07220060 with Letrozole combination Escalation

CDK4 inhibitor

Endocrine Therapy

다른 이름들:
  • 페마라
실험적: 1B Combination Dose Finding Arm 2

PF-07220060 with Letrozole Combination Escalation

CDK4 inhibitor

Endocrine Therapy

다른 이름들:
  • 페마라
실험적: 1C Combination Dose Finding Arm 1

PF-07220060 with Fulvestrant Combination Escalation

CDK4 inhibitor

Endocrine Therapy

다른 이름들:
  • 파슬로덱스
실험적: 1C Combination Dose Finding Arm 2

PF-07220060 with Fulvestrant Combination Escalation

CDK4 inhibitor

Endocrine Therapy

다른 이름들:
  • 파슬로덱스
실험적: 1D Monotherapy Food Effect

PF-07220060 Monotherapy Food Effect

CDK4 inhibitor

다른: 1E DDI Cohort

PF-07220060 DDI with Midazolam

CDK4 inhibitor

Benzodiazepine

실험적: 1F Combination Dose Finding

PF-07220060 with Enzalutamide Escalation

CDK4 inhibitor

Androgen Receptor inhibitor

다른 이름들:
  • 엑스탄디
실험적: 1G Combination Dose Finding Arm 1

PF-07220060 with Tamoxifen Combination De-Escalation

CDK4 inhibitor

Endocrine Therapy

실험적: 2A Combination Dose Expansion

PF-07220060 with fulvestrant combination expansion

CDK4 inhibitor

Endocrine Therapy

다른 이름들:
  • 파슬로덱스
실험적: 2B Combination Dose Expansion

PF-07220060 with Letrozole Combination Expansion

CDK4 inhibitor

Endocrine Therapy

다른 이름들:
  • 페마라
실험적: 2C Combination Dose Expansion

PF-07220060 with fulvestrant Combination Expansion

CDK4 inhibitor

Endocrine Therapy

다른 이름들:
  • 파슬로덱스
실험적: 2E Combination Dose Expansion

PF-07220060 Monotherapy OR PF-07220060 plus fulvestrant combination therapy

CDK4 inhibitor

Endocrine Therapy

다른 이름들:
  • 파슬로덱스
실험적: 2F Combination Dose Expansion

PF-07220060 with Tamoxifen Combination Expansion

CDK4 inhibitor

Endocrine Therapy

실험적: Giredestrant Combination Cohort (Group A)

PF-07220060 with Giredestrant Combination

CDK4 inhibitor

Endocrine Therapy

실험적: Giredestrant Combination Cohort (Group B)

PF-07220060 with Giredestrant Combination

CDK4 inhibitor

Endocrine Therapy

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of participants with dose limiting toxicities in the Dose Escalation or De-escalation Portion
기간: At the end of Cycle 1 (each cycle is 28 days)

First cycle (28 days) dose limiting toxicities

At the end of Cycle 1 (each cycle is 28 days)
Incidence of clinically significant AEs
기간: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months

Adverse Events

Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Incidence of clinically significant laboratory assessments
기간: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months

safety laboratory abnormalities

Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Incidence of clinically significant abnormal vital and ECG parameters
기간: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months

vital signs and heart rate corrected QT interval

Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Maximal Plasma Concentration (Cmax) of PF-07220060 given with and without food
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D)

Cycle 1 (each cycle is 28 days)
Time to Maximum Plasma Concentration (Tmax) of PF-07220060 given with and without food
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D)

Cycle 1 (each cycle is 28 days)
Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point (AUClast) of PF-07220060 given with and without food
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Part 1D)

Cycle 1 (each cycle is 28 days)
Maximal Plasma Concentration (Cmax) of Midazolam with and without PF-07220060
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E)

Cycle 1 (each cycle is 28 days)
Time to Maximum Plasma Concentration (Tmax) of Midazolam with and without PF-07220060
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E)

Cycle 1 (each cycle is 28 days)
Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Timepoint (AUClast) of Midazolam with and without PF-07220060
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Part 1E)

Cycle 1 (each cycle is 28 days)
Steady State Maximal Concentration (Cmax,ss) of PF-07220060
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days)
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of PF-07220060
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of PF-07220060
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days)
Steady State Minimum Plasma Concentration (Cmin,ss) of PF-07220060
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days)
Steady State Maximal Concentration (Cmax,ss) of Giredestrant
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days)
Steady State Time to Maximum Plasma Concentration (Tmax,ss) of Giredestrant
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCτ,ss) of Giredestrant
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days)
Steady State Minimum Plasma Concentration (Cmin,ss) of Giredestrant
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days)

2차 결과 측정

결과 측정
측정값 설명
기간
Single Dose: Maximal Plasma Concentration (Cmax) in the Dose Escalation and Dose Finding portion
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1F)

Cycle 1 (each cycle is 28 days)
Single Dose: Time to Maximum Plasma Concentration (Tmax) in the Dose Escalation and Dose Finding portion
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1F)

Cycle 1 (each cycle is 28 days)
Single Dose: Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Last Sampling Time Point Within the Dose Interval (AUClast) in the Dose Escalation and Dose Finding portion
기간: Cycle 1 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1F)

Cycle 1 (each cycle is 28 days)
Multiple Dose: Steady State Maximal Concentration (Cmax,ss) in the Dose Escalation and Dose Finding portion
기간: Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1E, 1F, 1G)

Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G
Multiple Dose: Steady State Time to Maximum Plasma Concentration (Tmax,ss) in the Dose Escalation and Dose Finding portion
기간: Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1E, 1F, 1G)

Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCt,ss) in the Dose Escalation and Dose Finding portion
기간: Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1E, 1F, 1G)

Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G
Multiple Dose: Steady State Minimum Plasma Concentration (Cmin,ss) in the Dose Escalation and Dose Finding portion
기간: Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 1A, 1B, 1C, 1E, 1F, 1G)

Cycle 1 (each cycle is 28 days) for Parts 1A/1B/1C/1E/1F; Cycle 2 (each cycle is 28 days) for Part 1G
Steady State Peak Concentration of Enzalutamide and N-desmethyl Enzalutamide
기간: Cycles 1 - 12 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for enzalutamide (Part 1F)

Cycles 1 - 12 (each cycle is 28 days)
Steady State Trough Concentration of Enzalutamide and N-desmethyl Enzalutamide
기간: Cycle 3 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for enzalutamide (Part 1F)

Cycle 3 (each cycle is 28 days)
Tumor Response per RECIST v1.1 and per PCGW3
기간: baseline up to approximately 24 months

Per RECIST v1.1 (all cohorts except for Part 1F); per PCWG3 (Part 1F)

baseline up to approximately 24 months
Duration of Response (DOR)
기간: baseline up to approximately 24 months

Per RECIST v1.1

baseline up to approximately 24 months
Progression Free Survival (PFS)
기간: baseline up to approximately 24 months

PFS per RECIST v.1.1

baseline up to approximately 24 months
Clinical Benefit Rate (CBR)
기간: baseline up to approximately 24 months

CBR per RECIST v1.1

baseline up to approximately 24 months
PSA50
기간: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months

Part 1F

Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Incidence of clinically significant AEs
기간: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months

Adverse Events (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Incidence of clinically significant laboratory assessments
기간: Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months

Safety laboratory abnormalities (Giredestrant Combination Cohort)

Cycle 1 (each cycle is 28 days) through study completion, up to approximately 24 months
Steady State Minimal Concentration (Cmin,ss) of Tamoxifen, 4-hydroxy-tamoxifen, N-desmethyltamoxifen, and Endoxifen
기간: Cycle 2 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for tamoxifen and metabolites (Parts 1G and 2F)

Cycle 2 (each cycle is 28 days)
Metabolite to Parent Ratio of Minimal Concentration (MRCmin) of 4-hydroxy-tamoxifen, N-desmethyltamoxifen, and Endoxifen
기간: Cycle 2 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for tamoxifen and metabolites (Parts 1G and 2F)

Cycle 2 (each cycle is 28 days)
Steady State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCt,ss) of Tamoxifen, 4-hydroxy-tamoxifen, N-desmethyltamoxifen, and Endoxifen
기간: Cycle 2 (each cycle is 28 days)

Pharmacokinetic (PK) assessments for tamoxifen and metabolites (Parts 1G and 2F)

Cycle 2 (each cycle is 28 days)
Steady State Peak Concentration of PF-07220060
기간: Cycle 1 (each cycle is 28 days) for Part 2A/2B/2C/2E; Cycle 2 (each cycle is 28 days) for Part 2F

Pharmacokinetic (PK) assessments for PF-07220060 (Part 2A, 2B, 2C, 2E, 2F)

Cycle 1 (each cycle is 28 days) for Part 2A/2B/2C/2E; Cycle 2 (each cycle is 28 days) for Part 2F
Steady State Trough Concentration of PF-07220060
기간: Cycle 1 (each cycle is 28 days) for Parts 2A/2B/2C/2E; Cycle 2 (each cycle is 28 days) for Part 2F

Pharmacokinetic (PK) assessments for PF-07220060 (Parts 2A, 2B, 2C, 2E, 2F)

Cycle 1 (each cycle is 28 days) for Parts 2A/2B/2C/2E; Cycle 2 (each cycle is 28 days) for Part 2F

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Pfizer CT.gov Call Center, Pfizer

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2020년 9월 23일

기본 완료 (추정된)

2029년 10월 7일

연구 완료 (추정된)

2029년 10월 7일

연구 등록 날짜

최초 제출

2020년 9월 15일

QC 기준을 충족하는 최초 제출

2020년 9월 15일

처음 게시됨 (실제)

2020년 9월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • C4391001
  • 2020-002938-33 (EudraCT 번호)
  • 2024-512120-11-00 (레지스트리 식별자: CTIS (EU))

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .